Bristol Gate Capital Partners Inc. lessened its stake in Danaher Co. (NYSE:DHR) by 2.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 346,831 shares of the conglomerate’s stock after selling 9,352 shares during the quarter. Danaher comprises 4.5% of Bristol Gate Capital Partners Inc.’s investment portfolio, making the stock its 14th biggest position. Bristol Gate Capital Partners Inc.’s holdings in Danaher were worth $32,193,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. ETRADE Capital Management LLC raised its stake in Danaher by 5.1% in the second quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after purchasing an additional 917 shares in the last quarter. Roundview Capital LLC raised its stake in Danaher by 2.0% in the second quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after purchasing an additional 502 shares in the last quarter. Honeywell International Inc. raised its stake in Danaher by 113.4% in the third quarter. Honeywell International Inc. now owns 640,100 shares of the conglomerate’s stock valued at $54,908,000 after purchasing an additional 340,100 shares in the last quarter. Veritable L.P. raised its stake in Danaher by 28.2% in the second quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock valued at $3,417,000 after purchasing an additional 8,912 shares in the last quarter. Finally, Wealthfront Inc. raised its stake in Danaher by 10.2% in the second quarter. Wealthfront Inc. now owns 14,574 shares of the conglomerate’s stock valued at $1,230,000 after purchasing an additional 1,348 shares in the last quarter. 76.19% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total value of $4,397,242.52. Following the completion of the transaction, the senior vice president now directly owns 82,008 shares of the company’s stock, valued at approximately $8,388,598.32. The disclosure for this sale can be found here. Insiders sold 274,913 shares of company stock valued at $27,729,293 in the last ninety days. 12.20% of the stock is currently owned by insiders.

Danaher Co. (DHR) opened at $94.46 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market capitalization of $67,350.00, a PE ratio of 26.99, a price-to-earnings-growth ratio of 1.94 and a beta of 1.04. Danaher Co. has a 52 week low of $78.97 and a 52 week high of $104.82.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.03. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.05 earnings per share. sell-side analysts forecast that Danaher Co. will post 4.37 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Thursday, December 28th. Danaher’s dividend payout ratio is currently 16.00%.

A number of research analysts recently commented on the company. Argus boosted their price target on Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Royal Bank of Canada reaffirmed a “hold” rating and issued a $98.00 price target on shares of Danaher in a research note on Wednesday, January 31st. Stifel Nicolaus boosted their price target on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Morgan Stanley boosted their price target on Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Finally, Credit Suisse Group boosted their target price on Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Danaher currently has an average rating of “Buy” and an average target price of $100.13.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/bristol-gate-capital-partners-inc-has-32-19-million-position-in-danaher-co-dhr/1858829.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.